CompletedPhase 2NCT02470091
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Studying Osteosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Katherine A Janeway, M.DChildren's Oncology Group
- Intervention
- Denosumab(biological)
- Enrollment
- 56 target
- Eligibility
- 11-49 years · All sexes
- Timeline
- 2015 – 2023
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim, Anaheim, California, United States
- Kaiser Permanente-Bellflower, Bellflower, California, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Kaiser Permanente-Fontana, Fontana, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02470091 on ClinicalTrials.govOther trials for Osteosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07477457A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06492954Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaEmory University
- RECRUITINGNANCT07129226Musculoskeletal Cancers Remote Monitoring and CareCase Comprehensive Cancer Center
- RECRUITINGPHASE1NCT07144254Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaEmory University
- RECRUITINGPHASE1NCT07227571Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe TrialFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07052383Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasTcelltech Inc.
- RECRUITINGPHASE1, PHASE2NCT06892678DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaMontefiore Medical Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05660408RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid TumorsUniversity of Florida